“COMPARISON OF EFFICACY OF LOW DOSE AND HIGH DOSE SORAFENIB IN PATIENTS OF HEPATOCELLULAR CARCINOMA”

Authors

  • Dr Omer Hassaan Aftab Ahmad
  • Dr Sher Alam
  • Dr Shan Alam
  • Dr Abid Ali Rana
  • Dr Muhammad Waseem Sharif
  • Dr Tanveer Ahmed

DOI:

https://doi.org/10.53555/e15m1d66

Keywords:

Hepatocellular carcinoma; Sorafenib; Low-dose therapy; High-dose therapy; Drug efficacy; Adverse effects; Progression-free survival; Targeted therapy; Cost-effectiveness; multiple centers including Bahawal Victoria Hospital Bahawalpur, Sheikh Zayad Teaching Hospital and Omer diagnostic and specialist hospital Islamabad.

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths all over the world, and there are few treatment options in the case of advanced disease. Sorafenib is a multikinase inhibitor, which is the standard systemic therapy for unresectable HCC. However, the best dose that is acceptable and at the same time effective is still in debate, particularly in countries with limited resources, such as Pakistan.

Objective: To compare the efficacy and safety of low-dose and high-dose sorafenib in patients with hepatocellular carcinoma in JPMC, Karachi.

Methods: The proposed comparative study was conducted at multiple centers including Bahawal Victoria Hospital Bahawalpur, Sheikh Zayad Teaching Hospital and Omer diagnostic and specialist hospital Islamabad. Total 80 patients with confirmed HCC during the period between March 2024 to February, 2025. Group A was low-dose sorafenib (200mg twice a day), and Group B was high-dose sorafenib (400mg twice a day). The tumor response was evaluated using the assistance of the RECIST 1.1 criteria, and the adverse events were assessed using the CTCAE v5.0 criteria.

Results: The overall response rate of the low-dose group was 45% and the high-dose group was 57.5% (p = 0.21). The progression-free survival was a little higher in the high-dose group (7.4 months vs. 6.8 months), but the difference was not significant. Nevertheless, poisoning related to treatment, including hand-foot skin reaction and diarrhea, was much more common with the high-dose group (p < 0.05).

Conclusion: The low-dose sorafenib showed a similar effect to the high-dose regimen but with significantly fewer side effects. It is a safer, cost-effective, and better-tolerated therapy for patients with hepatocellular carcinoma in Pakistan.

Author Biographies

  • Dr Omer Hassaan Aftab Ahmad

    Consultant Gastroenterologist, Omer Diagnostics and Specialist Clinics G8 Markaz, Islamabad

  • Dr Sher Alam

    Consultant and Assistant Professor Gastroenterology, Shaikh Zayed University Teaching Hospital

  • Dr Shan Alam

    Senior Gastroenterologist, DHQ Hospital Gilgit

  • Dr Abid Ali Rana

    Assistant Professor Gastroenterology, Bahawal Victoria Hospital Bahawalpur

  • Dr Muhammad Waseem Sharif

    Medical Officer, Bahawal Victoria Hospital Bahawalpur

  • Dr Tanveer Ahmed

    Senior Registrar Gastroenterology, Bahawal Victoria Hospital Bahawalpur

References

1. Fulgenzi, C. A., D'Alessio, A., Airoldi, C., Scotti, L., Demirtas, C. O., Gennari, A., Cortellini, A., & Pinato, D. J. (2022). Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network meta-analysis of phase III trials. European Journal of Cancer, 174, 57–67.

2. Quan, W., Fazlin Zulkifli, H., Saari, N., Shueb, R. H., & Mustaffa, N. (2025). Comparison of efficacy and safety of adjuvant therapies versus sorafenib in hepatocellular carcinoma: A systematic review and network meta-analysis. Frontiers in Pharmacology, 16, 1502931.

3. Leung, J. H., Wang, S. Y., Leung, H. W., & Chan, A. L. (2024). Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: Patient-level network meta-analysis. Frontiers in Oncology, 14, 1344798.

4. Li, J. F., Fu, Y. X., Zhang, H. C., Ma, H., Yuan, G. J., & Tan, Y. (2023). Comparing the clinical efficacy and safety of second-line targeted therapy and immunotherapy in patients with mid-to advanced stages of hepatocellular carcinoma: A systematic review and meta-analysis of randomized clinical trials. European Review for Medical & Pharmacological Sciences, 27(22).

5. Chen, J., He, K., Han, Y., Guo, L., Su, K., & Wu, Z. (2022). Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Annals of Hepatology, 27(4), 100710.

6. Li, J. F., Fu, Y. X., Zhang, H. C., Ma, H., Yuan, G. J., & Tan, Y. (2023). Comparing the clinical efficacy and safety of second-line targeted therapy and immunotherapy in patients with mid-to advanced stages of hepatocellular carcinoma: A systematic review and meta-analysis of randomized clinical trials. European Review for Medical & Pharmacological Sciences, 27(22).

7. Li, Z., Gao, J., Zheng, S., Wang, Y., Xiang, X., Cheng, Q., & Zhu, J. (2021). Therapeutic efficacy of sorafenib in patients with hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis. The Turkish Journal of Gastroenterology, 32(1), 30–38.

8. Siddharth, S., Kuppusamy, P., Wu, Q., Nagalingam, A., Saxena, N. K., & Sharma, D. (2022). Metformin enhances the anti-cancer efficacy of sorafenib via suppressing MAPK/ERK/STAT3 axis in hepatocellular carcinoma. International Journal of Molecular Sciences, 23(15), 8083.

9. Garg, V., Gangadharaiah, B. B., Rastogi, S., Upadhyay, A., Barwad, A., Dhamija, E., & Gamangatti, S. (2023). Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose. European Journal of Cancer, 186, 142–150.

10. Huang, S., Li, D., Zhuang, L., Sun, L., & Wu, J. (2021). A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. World Journal of Surgical Oncology, 19(1), 168.

11. Singh, D., Khan, M. A., Mishra, D., Goel, A., Ansari, M. A., Akhtar, K., & Siddique, H. R. (2024). Apigenin enhances sorafenib anti-tumour efficacy in hepatocellular carcinoma. Translational Oncology, 43, 101920.

12. Gnocchi, D., Castellaneta, F., Cesari, G., Fiore, G., Sabbà, C., & Mazzocca, A. (2021). Treatment of liver cancer cells with ethyl acetate extract of Crithmum maritimum permits reducing sorafenib dose and toxicity while maintaining its efficacy. Journal of Pharmacy and Pharmacology, 73(10), 1369–1376.

13. Ng, W. H., Soo, K. C., & Huynh, H. (2024). Vinorelbine improves the efficacy of sorafenib against hepatocellular carcinoma: A promising therapeutic approach. International Journal of Molecular Sciences, 25(3), 1563.

14. Hajiev, S., Allara, E., Motedayen Aval, L., Arizumi, T., Bettinger, D., Pirisi, M., Rimassa, L., Pressiani, T., Personeni, N., Giordano, L., & Kudo, M. (2021). Impact of age on sorafenib outcomes in hepatocellular carcinoma: An international cohort study. British Journal of Cancer, 124(2), 407–413.

15. Zehra, D., Memon, Z., Usman, S., Jabeen, A., Ismail, K., & Siddiqui, R. A. (2022). Low dose of azithromycin enhances the anticancer efficacy of sorafenib in HepG2 cell line. Pakistan Journal of Zoology, 54(3).

16. Gopakumar, L., Sreeranganathan, M., Chappan, S., James, S., Gowd, G. S., Manohar, M., Sukumaran, A., Unni, A. K., Nair, S. V., & Koyakutty, M. (2022). Enhanced oral bioavailability and antitumor therapeutic efficacy of sorafenib administered in core–shell protein nanoparticle. Drug Delivery and Translational Research, 12(11), 2824–2837.

17. Irawan, A., Prabowo, E., Riwanto, I., & Atmodjo, W. L. (2022). Anti-angiogenic effect of the combination of low-dose sorafenib and EGCG in HCC-induced Wistar rats. F1000Research, 11, 289.

18. He, Y., Zhan, L., Shi, J., Xiao, M., Zuo, R., Wang, C., Liu, Z., Gong, W., Chen, L., Luo, Y., & Zhang, S. (2023). The combination of R848 with sorafenib enhances antitumor effects by reprogramming the tumor immune microenvironment and facilitating vascular normalization in hepatocellular carcinoma. Advanced Science, 10(18), 2207650.

Downloads

Published

2025-11-10

How to Cite

Dr Omer Hassaan Aftab Ahmad, Dr Sher Alam, Dr Shan Alam, Dr Abid Ali Rana, Dr Muhammad Waseem Sharif, & Dr Tanveer Ahmed. (2025). “COMPARISON OF EFFICACY OF LOW DOSE AND HIGH DOSE SORAFENIB IN PATIENTS OF HEPATOCELLULAR CARCINOMA”. Journal of Population Therapeutics and Clinical Pharmacology, 32(10), 328-336. https://doi.org/10.53555/e15m1d66
More Citation Formats

Issue

Section

Articles

How to Cite

Dr Omer Hassaan Aftab Ahmad, Dr Sher Alam, Dr Shan Alam, Dr Abid Ali Rana, Dr Muhammad Waseem Sharif, & Dr Tanveer Ahmed. (2025). “COMPARISON OF EFFICACY OF LOW DOSE AND HIGH DOSE SORAFENIB IN PATIENTS OF HEPATOCELLULAR CARCINOMA”. Journal of Population Therapeutics and Clinical Pharmacology, 32(10), 328-336. https://doi.org/10.53555/e15m1d66